Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768496 | 0.81 | KDR (0.43) | KDRNPC1RAB9AKITFLT3 | |
| SCHEMBL2768161 | 0.77 | KDR (0.50) | KDRSMN1; SMN2NPC1LRRK2RAB9A | |
| SCHEMBL2768466 | 0.76 | NPSR1 (0.47) | SMN1; SMN2NPC1RAB9AGAAALDH1A1 | |
| SCHEMBL2768184 | 0.70 | MAP2K4 (0.42) | KDRNPC1LRRK2KITFLT3 | |
| SCHEMBL2770623 | 0.70 | KDR (0.56) | KDRNPC1LRRK2RAB9AKIT | |
| SCHEMBL2769034 | 0.70 | ALDH1A1 (0.46) | KDRSMN1; SMN2NPC1RAB9ACHEK1 | |
| SCHEMBL2866826 | 0.67 | DYRK1A (0.52) | KDRLRRK2MAPK8MAP4K4CSNK1D | |
| SCHEMBL29549962 | 0.66 | KDR (1.00) | KDR | |
| SCHEMBL17034074 | 0.66 | KDR (1.00) | KDR | |
| SCHEMBL13635734 | 0.65 | DYRK1A (0.52) | KDRLRRK2CRHR1MAPK8MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1479670-B1 | NOVEL FUSED RING INDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-04-21 | — | — | EP | disclosed |
| EP-1479670-B1 | NOVEL FUSED RING INDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-7390797-B2 | Fused indazole compounds | EISAI CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-7390797-B2 | Fused indazole compounds | EISAI CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-7390797-B2 | Fused indazole compounds | EISAI CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060111419-A1 | Novel fused indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1479670-A1 | NOVEL FUSED RING INDAZOLE COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111419-A1 | Novel fused indazole compounds | MAP2K3, MAP3K11, MAP2K2 | KDR 3156/4885SMN1; SMN2 4492/4885NPC1 1991/4885 |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | KDR 3572/4885SMN1; SMN2 1950/4885NPC1 4384/4885 |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | MAPK9, IAPP, RNASE1 | KDR 3572/4885SMN1; SMN2 1950/4885NPC1 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.